Enanta Pharmaceuticals, Inc. V. Pfizer Inc. (D. Mass. 22-cv-10967; Fed. Cir. 25-1427).
Enanta Pharmaceuticals appealed a Massachusetts court ruling that its U.S. Patent No. 11,358,953 was invalid, finding the patent improperly broadened “substituted” alkyls from C2-C12 to C1-C12 and that Pfizer’s later public disclosure anticipated the claims. The Federal Circuit affirmed, ruling the provisional lacked written description support for C1 alkyl coverage.
How this was made
The 30-second read
Why it matters
The Federal Circuit affirmed that the provisional priority did not support claims covering C1 alkyls, and that Pfizer’s later disclosure anticipated the asserted claims.
Market read
A patent invalidity affirmance is a direct hit to the enforceability of Enanta’s asserted IP, which can affect expectations for licensing, exclusivity, and competitive positioning.
What to watch
The article does not quantify damages, remaining claim scope, or whether other asserted patents in the same family survive, which could materially change the economic impact.
Background
Enanta appealed a district court summary judgment invalidating its ‘953 patent covering COVID-19 enzyme-inhibiting compounds.
Market effects
Reinforces strict written-description standards in pharma patent prosecution and can pressure valuation of similar early-stage compound families.
US-focused appellate outcome may affect US biotech litigation sentiment.
US patent validity outcomes can influence global exclusivity strategies and licensing negotiations.
Counterpoint
Even with invalidity of this specific ‘953 patent, Enanta may still have other patents, formulations, or non-patent exclusivity that limit competitive impact.
Key entities
- companyEnanta Pharmaceuticals, Inc.
Plaintiff-appellant seeking to overturn invalidity of its ‘953 patent.
- companyPfizer Inc.
Accused infringer whose public disclosure was used to support anticipation findings.
- courtFederal Circuit
Appellate court that affirmed the district court’s summary judgment of invalidity.
